


REMARKS

The present application relates to a novel medicinal composition that restores, corrects or modulates an organic function in a human or an animal which comprises an effective amount of at least one of 12-HETE, 11,12-EET or a combination thereof. The present application is also directed toward a method for inhibiting the differentiation of a fibroblast to an adipocyte.

Claims 1-3 are cancelled, Claims 4-18 are new and by entry of this amendment Claims 4-18 are pending. The new claims do not introduce new matter into the above identified application. Support for the new claims may be found throughout the specification.

Favorable consideration of the pending claims is respectfully requested. If the Examiner believes there are other issues that can be resolved by telephone interview, or that there are any informalities remaining in the application that may be corrected by Examiner's Amendment, a telephone call to the undersigned attorney at (404) 745-2470 is respectfully solicited. Should any additional fees be required in connection with the filing of this preliminary amendment, the Commissioner is hereby authorized to charge the same to Deposit Account No. 11-0855.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "John K. McDonald".

John K. McDonald, Ph.D.
Reg. No. 42,860

KILPATRICK STOCKTON LLP
1100 Peachtree Street
Suite 2800
Atlanta, Georgia 30309
(404) 815-6500
Docket: 16721-0210 (42528-288279)